Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 17 participantsVery low
The review found no eligible studies for this question.
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).